Matinas BioPharma Files 2024 10-K
Ticker: MTNB · Form: 10-K · Filed: Apr 15, 2025 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | 10-K |
| Filed Date | Apr 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, annual-report, financials
TL;DR
Matinas BioPharma dropped its 2024 10-K. Check financials.
AI Summary
Matinas BioPharma Holdings, Inc. filed its 2024 10-K on April 15, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in Bedminster, NJ, operates in the pharmaceutical preparations sector. The filing details financial performance and business operations for the period, with specific financial data points to be elaborated upon in the full report.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Matinas BioPharma's financial health and strategic direction for the fiscal year 2024, crucial for understanding the company's performance and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Matinas BioPharma is subject to significant regulatory, clinical, and market risks inherent in drug development and commercialization.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-04-15 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-04-15 (date) — Filing date
- Bedminster, NJ (location) — Company business address
- PHARMACEUTICAL PREPARATIONS [2834] (industry) — Standard Industrial Classification
FAQ
What was Matinas BioPharma's net income or loss for the fiscal year ended December 31, 2024?
The provided filing header does not contain specific net income or loss figures for the fiscal year ended December 31, 2024. This information would be detailed within the full 10-K report.
What were the total revenues for Matinas BioPharma in 2024?
The filing header does not specify total revenues for the fiscal year ended December 31, 2024. This detail is expected to be found within the financial statements of the full 10-K.
What is the company's cash and cash equivalents balance as of December 31, 2024?
Specific figures for cash and cash equivalents as of December 31, 2024, are not present in the provided header information and would be detailed in the balance sheet section of the 10-K.
What are the primary business segments or product candidates discussed in the 2024 10-K?
The header indicates Matinas BioPharma Holdings, Inc. is in 'PHARMACEUTICAL PREPARATIONS [2834]', but specific product candidates or business segments are not detailed in this excerpt.
Were there any significant changes in the company's capital structure or debt during the fiscal year 2024?
The filing header lists various financial statement members like 'CommonStockMember', 'AdditionalPaidInCapitalMember', 'RetainedEarningsMember', and 'AccumulatedOtherComprehensiveIncomeMember' for different periods, suggesting financial activities, but specific debt changes are not detailed here.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on April 15, 2025 regarding Matinas BioPharma Holdings, Inc. (MTNB).